HCA Healthcare (HCA)
NYSEHealth CareMedical Care FacilitiesSnapshot 2026-07-07
$423.10+1.45%
Close 2026-07-07 · 1-day change
Reading HCA? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track HCA free→NYSEHealth CareMedical Care FacilitiesSnapshot 2026-07-07
Reading HCA? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track HCA free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder with a focus on healthcare services. The current thesis is intact, supported by strong recent financial performance and ongoing share buybacks, though management execution remains volatile.
The market currently prices HCA as cheap compared to its peers, with a significant expectations gap. There is a low level of fragility in the stock, indicating that the current valuation is justified given the company's fundamentals.
Management is on track with its revenue guidance and share buyback program, which supports a stable outlook. However, there is a moderate risk due to recent management changes and a history of earnings misses.
The thesis hinges on the ability of HCA to reaffirm its revenue guidance and the performance of sector bellwethers like THC, DVA, and EHC. Positive momentum in the healthcare sector could benefit HCA, while any negative guidance from peers could pose risks.
Overall, HCA's fundamentals appear solid for the next 1 to 3 years, but investor sentiment may shift based on sector performance and management execution. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The reaffirmation of 2026 revenue guidance, supported by recent advancements such as the Cigna pact and clinic expansion, reinforces the positive outlook for HCA. There are no current threats noted that would detract from this improved assessment.
as of 2026-07-07
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Sticking to revenue goals shows the company is stable and trustworthy.
Confirms:Management reaffirms 2026 revenue guidance of $76.5 billion to $80 billion in Q2 2026.
Disproves:Management lowers the 2026 revenue guidance to below $76.5 billion in Q2 2026.
Why it matters: Same facility admissions growth is key for revenue stability. A decline would raise concerns.
Confirms:Same facility admissions growth below 0.5% year over year in Q2 2026.
Disproves:Same facility admissions growth above 1.0% year over year in Q2 2026.
Why it matters: Changes in spending can affect growth and capacity. It shows management's plan.
Confirms one read:Capital spending for 2026 is set between $5.0 billion and $5.5 billion.
Confirms the other:Capital spending is changed a lot. It is now outside the current range.
Why it matters: Changes in spending can affect growth and how well the company operates.
Confirms one read:Management says capital spending is steady or going up.
Confirms the other:Management says it will cut capital spending.
Why it matters: A drop in sector revenue growth could signal broader issues affecting HCA's performance.
Confirms:Sector revenue growth falls below its median for the first time.
Disproves:Sector revenue growth remains above its median.
Why it matters: Changes in spending show management's plan and ability to invest in growth.
Confirms one read:Spending in Q2 2026 is over $1.5 billion.
Confirms the other:Spending in Q2 2026 is below $1 billion.
Why it matters: Updates on the buyback program show that management believes in cash flow and stock value.
Confirms:They announced more share buybacks over $1 billion in Q2 2026.
Disproves:No new announcements on share repurchases in Q2 2026.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.